Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
ANTH's Cash to Debt is ranked higher than
82% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ANTH: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANTH' s Cash to Debt Range Over the Past 10 Years
Min: 0.29  Med: 2.77 Max: No Debt
Current: No Debt
Equity to Asset 0.82
ANTH's Equity to Asset is ranked higher than
69% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ANTH: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
ANTH' s Equity to Asset Range Over the Past 10 Years
Min: 0.82  Med: 0.82 Max: 0.82
Current: 0.82
F-Score: 5
Z-Score: 0.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1106.53
ANTH's Operating margin (%) is ranked lower than
79% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. ANTH: -1106.53 )
Ranked among companies with meaningful Operating margin (%) only.
ANTH' s Operating margin (%) Range Over the Past 10 Years
Min: -1106.53  Med: -1106.53 Max: -1106.53
Current: -1106.53
Net-margin (%) -1105.81
ANTH's Net-margin (%) is ranked lower than
80% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. ANTH: -1105.81 )
Ranked among companies with meaningful Net-margin (%) only.
ANTH' s Net-margin (%) Range Over the Past 10 Years
Min: -1105.81  Med: -1105.81 Max: -1105.81
Current: -1105.81
ROE (%) -121.67
ANTH's ROE (%) is ranked lower than
85% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. ANTH: -121.67 )
Ranked among companies with meaningful ROE (%) only.
ANTH' s ROE (%) Range Over the Past 10 Years
Min: -763.58  Med: -361.77 Max: -179.7
Current: -121.67
-763.58
-179.7
ROA (%) -92.83
ANTH's ROA (%) is ranked lower than
87% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. ANTH: -92.83 )
Ranked among companies with meaningful ROA (%) only.
ANTH' s ROA (%) Range Over the Past 10 Years
Min: -254.43  Med: -138.98 Max: -96.65
Current: -92.83
-254.43
-96.65
ROC (Joel Greenblatt) (%) -9353.24
ANTH's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ANTH: -9353.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANTH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -238386.67  Med: -12024.46 Max: -2880.94
Current: -9353.24
-238386.67
-2880.94
EBITDA Growth (3Y)(%) -49.70
ANTH's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 497 Companies
in the Global Biotechnology industry.

( Industry Median: -0.30 vs. ANTH: -49.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANTH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -55.05 Max: -49.7
Current: -49.7
EPS Growth (3Y)(%) -46.00
ANTH's EPS Growth (3Y)(%) is ranked lower than
89% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ANTH: -46.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANTH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -57.00 Max: -46
Current: -46
» ANTH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ANTH Guru Trades in Q1 2015

Jim Simons 18,303 sh (New)
» More
Q2 2015

ANTH Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q3 2015

ANTH Guru Trades in Q3 2015

Jim Simons 169,000 sh (New)
» More
Q4 2015

ANTH Guru Trades in Q4 2015

Jim Simons 269,000 sh (+59.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ANTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.74
ANTH's P/B is ranked lower than
60% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. ANTH: 3.74 )
Ranked among companies with meaningful P/B only.
ANTH' s P/B Range Over the Past 10 Years
Min: 2.69  Med: 5.05 Max: 16.09
Current: 3.74
2.69
16.09
P/S 41.13
ANTH's P/S is ranked lower than
78% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. ANTH: 41.13 )
Ranked among companies with meaningful P/S only.
ANTH' s P/S Range Over the Past 10 Years
Min: 29.67  Med: 195.42 Max: 680
Current: 41.13
29.67
680
Current Ratio 5.65
ANTH's Current Ratio is ranked higher than
57% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ANTH: 5.65 )
Ranked among companies with meaningful Current Ratio only.
ANTH' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.34 Max: 8.15
Current: 5.65
0.21
8.15
Quick Ratio 5.65
ANTH's Quick Ratio is ranked higher than
59% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ANTH: 5.65 )
Ranked among companies with meaningful Quick Ratio only.
ANTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.34 Max: 8.15
Current: 5.65
0.21
8.15
Days Sales Outstanding 37.36
ANTH's Days Sales Outstanding is ranked higher than
72% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. ANTH: 37.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.36  Med: 37.36 Max: 37.36
Current: 37.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.85
ANTH's Price/Net Cash is ranked higher than
58% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. ANTH: 3.85 )
Ranked among companies with meaningful Price/Net Cash only.
ANTH' s Price/Net Cash Range Over the Past 10 Years
Min: 2.9  Med: 9.84 Max: 18.06
Current: 3.85
2.9
18.06
Price/Net Current Asset Value 3.78
ANTH's Price/Net Current Asset Value is ranked higher than
59% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. ANTH: 3.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANTH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.8  Med: 9.53 Max: 16.16
Current: 3.78
2.8
16.16
Price/Tangible Book 3.74
ANTH's Price/Tangible Book is ranked lower than
51% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. ANTH: 3.74 )
Ranked among companies with meaningful Price/Tangible Book only.
ANTH' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.8  Med: 4.36 Max: 13.18
Current: 3.74
2.8
13.18
Price/Median PS Value 0.21
ANTH's Price/Median PS Value is ranked higher than
92% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ANTH: 0.21 )
Ranked among companies with meaningful Price/Median PS Value only.
ANTH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.26 Max: 0.26
Current: 0.21
Earnings Yield (Greenblatt) (%) -34.93
ANTH's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. ANTH: -34.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANTH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -112.9  Med: 0.00 Max: 0
Current: -34.93
-112.9
0

More Statistics

Revenue(Mil) $3
EPS $ -1.01
Beta2.84
Short Percentage of Float11.30%
52-Week Range $2.28 - 11.65
Shares Outstanding(Mil)40.00

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:AMPE, LSE:TRX, NAS:CYTR, AMEX:NAVB, XKRX:041910, NAS:PETX » details
Traded in other countries:6TA1.Germany,
Anthera Pharmaceuticals Inc was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflammation and autoimmune diseases. The Company's product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product development program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for ANTH

Headlines

Articles On GuruFocus.com
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 12 2010 
Weekly CFO Buys Highlight: Inuvo Inc., Heelys Inc., Peregrine Pharmaceuticals Inc., Anthera Pharmace Sep 26 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 12 2010 
Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change... Apr 29 2016
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors Apr 27 2016
Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors Apr 27 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 22 2016
Six Technologies That Will Change Healthcare Apr 07 2016
CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results Mar 29 2016
ANTHERA PHARMACEUTICALS INC Financials Mar 18 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 14 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 10 2016
Anthera reports 4Q loss Mar 10 2016
Anthera reports 4Q loss Mar 10 2016
Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year... Mar 10 2016
Q4 2015 Anthera Pharmaceuticals Inc Earnings Release - After Market Close Mar 10 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 08 2016
Anthera Pharmaceuticals Announces Appointment of Dr. James Pennington as Interim Chief Medical... Mar 07 2016
5 Things to Know Before Buying Anthera Pharmaceuticals (ANTH) Feb 21 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 17 2016
Aetna Has ‘Serious Concerns’ With ObamaCare Exchanges Feb 01 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 29 2016
ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK